FGF23 and hypophosphatemia: The Enpp1asj/asj and Enpp1asj‐2J models recapitulate the clinical features in humans with ENPP1 deficiency; low PPi, elevated FGF23, hypophosphatemia, arterial calcification, neointima proliferation, hearing loss, enthesopathies and early mortality as well as lower bone mass or osteomalacia, in heterozygous and homozygous mice (Cheng et al., 2021; Ferreira, Ansh, et al., 2022; Li et al., 2013, 2016; Oheim et al., 2020; Tian et al., 2016; Zimmerman et al., 2022).